NEW YORK, Sept. 20 – Merck's wholly owned subsidiary Rosetta Inpharmatics said Thursday it had established a new business unit, Rosetta Biosoftware, to develop and sell new bioinformatics software for life science research.
The new business unit, which will be based in Kirkland, Wash., will continue to develop new versions of Rosetta’s flagship product, the Rosetta Resolver Gene Expression Data Analysis System.
Agilent Technologies will remain the exclusive distributor of Rosetta software.